Ivy Brain Tumor Center
@IvyBrainTumCtr
Largest #Phase0 clinical trials program in the world providing personalized treatment options for patients with #glioblastoma & other aggressive brain tumors.
ID:996443337665085440
http://www.ivybraintumorcenter.org 15-05-2018 17:32:59
2,7K Tweets
4,6K Followers
2,9K Following
#WednesdayWarrior : Katie Reed was diagnosed with glioblastoma last year, but after surgery to remove the tumor, she enrolled in an Ivy Center clinical trial to test a new drug for glioblastoma. This drug crossed the blood-brain barrier, reached her tumor, and prevented growth.
Exciting #GBMNews from our friends at Ivy Brain Tumor Center β οΈ | The Gliofocus Study will evaluate niraparib compared to temozolomide in adult patients with newly diagnosed MGMT-unmethylated glioblastoma.
#Glioblastoma
Happy to share results from a new Phase 0 trial led by Ivy Brain Tumor Center Nader Sanai Shwetal Mehta, Ph.D. (she/her) and Kevin Johnson: Single nucleus transcriptomics, PK/PD of combined CDK4/6 and mTOR inhibition in a phase 0/1 trial of recurrent high-grade glioma medrxiv.org/content/10.110β¦
Are you or a loved one battling a recurrent high-grade glioma? Consider enrolling in an Ivy Center clinical trial to access novel investigational treatments. Connect with us today. π§ π¬
π loom.ly/TcA5c_g
βοΈ 602-406-8605
βοΈ [email protected]
At the Ivy Center, our dedication is to find a cure for brain cancer. On #WorldBrainTumorDay , we continue to push boundaries in brain tumor research to discover new, more effective therapies. Join us in raising awareness in the fight against brain tumors. ππ§
The Ivy Center is excited to welcome Sydney Canning to the team! Sydney earned her Bachelor of Science in Biochemistry from Arizona State University. Her expertise in performing molecular assays in clinical settings will make her a valuable addition to our pharmacodynamics team. Welcome, Sydney!π
We're incredibly thankful to the Oehme Foundation for their generous donation of $100,000 during Brain Tumor Awareness Month. This support is crucial for advancing research and providing hope to those affected by brain tumors.ππ§
Read the full story: loom.ly/xzGntoc
We are proud to sponsor the annual American Brain Tumor Association National Conference. This event looks at the latest breakthroughs in brain tumor research, treatment, & care. Don't miss this opportunity! Registration is now open!
π September 5-7, 2024
π Virtual & Chicago
π loom.ly/08unjhU
THANK YOU to our restaurant partners for supporting us & the Ivy Brain Tumor Center for #DineAndDonate ! π We are so grateful you decided to join arms with us to beat #braincancer & hope all who dined enjoyed your meal, knowing you are making a difference!
Promising interim survival & best in class brain penetration noted in this phase 0/2 Niraparib trial Ivy Brain Tumor Center in new GBM βοΈ Nader Sanai will be talking more about the upcoming phase 3 trial tonight at the meet the expert session!
Are you or a loved one battling a recurrent high-grade glioma? Consider enrolling in an Ivy Center clinical trial to access novel investigational treatments. Connect with us today. π§ π¬
π loom.ly/_YcKLPA
βοΈ 602-406-8605
βοΈ [email protected]
Attending #ASCO2024 ? Join us to hear from Dr. Nader Sanai on niraparib in #GBM and the upcoming #Gliofocus Study, a global Phase 3 trial. Learn about the study design, how to become a study investigator and chat with the Steering Committee. Register here: loom.ly/IgcbqNA
Insightful poster by Dr. Yoshie Umemura on BDTX-1535, assessing its PK, PD, & clinical responses in recurrent HGG & EGFR alterations. BDTX-1535 was well-tolerated, reaches effective concentrations in non-enhancing tumor tissue & is linked to the suppression of EGFR signaling.π
